These downloadable slides by Dr. Neal D. Shore, MD, FACS are on the topic of management of adverse effects in ADT for men with prostate cancer. These slides were presented at a satellite symposium presented in conjunction with the AUA Annual Meeting held on Sunday, May 14, 2017 entitled “Navigating the Adverse Effects of ADT: Improving Patient Outcomes”.
About The Author
Neal D. Shore, MD, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association. He also is a member of the AUA Data Committee, the Bladder Cancer Advocacy Think Tank and the editorial board of Urology Times. He has numerous articles/peer reviewed publications and also performs peer review for more multiple journals. A graduate of Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?